Reviewing the 2026 EADV Congress findings on precision biopsy profiling, long-term clinical data, and individualized care for inflammatory skin conditions.
In October 2026, Dermatology Times reported on the European Academy of Dermatology and Venereology Congress. The event took place in Vienna, Austria, from September 30 through October 3. According to the publication, the congress highlighted a significant shift in treating chronic inflammatory skin conditions. The focus is moving away from short-term symptom relief and toward durable disease control.
Presentations at the meeting covered late-breaking trials, long-term safety data, and emerging real-world evidence. Researchers also shared new information on genetics, biomarkers, and individualized patient care. The coverage reflects a shift in the primary questions being asked about inflammatory skin disease. Clinicians are evaluating whether a treatment improves initial signs and whether that benefit persists over time.
Medical professionals are also prioritizing how patients experience itch, sleep quality, and overall daily life. One of the most prominent topics at the congress was precision medicine. Dermatology Times described a presentation by Michel Gilliet, MD, who examined transcriptomic skin biopsy profiling. This technique analyzes molecular activity to identify the immune pathways driving an individual patient's condition.
The profiling maps inflammatory activity across Th17, Th2, and Th1 pathways. It also maps type I interferon, neutrophilic, macrophagic, and eosinophilic pathways. By understanding these exact mechanisms, doctors could eventually differentiate between overlapping clinical presentations. This could potentially explain some treatment failures and inform more precise treatment selection.
Sara Brown, MD, PhD, also explained how genetic insights clarify the role of skin barrier dysfunction. During her presentation, she discussed inflammatory pathways specifically related to atopic eczema. She noted that conditions like atopic dermatitis are not biologically uniform across all patients. Instead, they are highly individualized processes that require a nuanced approach to clinical care.
The congress featured extensive clinical trial data evaluating long-term outcomes in chronic skin conditions. For atopic dermatitis, Dermatology Times shared results from the ARCADIA clinical development program. This was an open-label long-term extension study of adults and adolescents with moderate-to-severe atopic dermatitis. At week 152, up to 91 percent of patients achieved an EASI-75 score.
The same study reported that up to 75 percent reached EASI-90. Additionally, up to 67 percent had clear or almost clear skin by Investigator’s Global Assessment. Furthermore, up to 88 percent achieved clinically meaningful itch relief. Up to 92 percent experienced clinically meaningful improvement in their dermatology-related quality of life.
Importantly, the ARCADIA report noted no new safety signals through three years of continuous treatment. For psoriasis, the phase 3 LATITUDE Atlas trial enrolled 606 adults with moderate-to-severe plaque psoriasis. The trial compared investigational zasocitinib at 30 mg once daily with deucravacitinib at 6 mg once daily. The researchers tracked patient progress through week 16 of the trial.
The report states that 62.5 percent of patients receiving zasocitinib achieved PASI-90. This is compared to 34.0 percent of those taking deucravacitinib. Clear skin by static Physician Global Assessment was achieved by 43.2 percent and 18.5 percent, respectively. A separate post hoc analysis found that up to 93 percent of initial responders maintained clearance later.
One study showed this maintenance through week 52, while another showed it through week 40. These findings reflect a growing clinical interest in oral therapies and new immune targets. The meeting’s reporting points to longer-term outcome tracking as a major priority in dermatology. However, clinical research has clear limitations that require careful and measured interpretation.
Dermatology Times notes that the ARCADIA figures are reported strictly as conditional values. The report omits the underlying patient counts and subgroup breakdowns needed to judge the data. It also omits the specific assessment instruments used for evaluating itch and quality of life. These missing details make it difficult to determine how representative the reported percentages truly are.
Additionally, the 93 percent maintenance rate in the psoriasis study comes from a post hoc analysis. It only applies to patients who had already responded favorably by week 24. A related Dermatology Times analysis advises readers to consider patient retention and discontinuations. Missing data methods also affect how these long-term extension results should be interpreted.
Molecular profiling is an emerging discussion rather than an established medical routine. The coverage does not provide validation metrics or regulatory status for this biopsy technique. Patients should not expect this type of testing at a standard clinic visit right now. Furthermore, while real-world evidence adds helpful information, it does not replace randomized controlled trials.
The Day 4 coverage characterized randomized trials and real-world evidence as highly complementary tools. Trials remain essential for establishing basic efficacy and overall patient safety. Real-world evidence may address longer-term safety and persistence in diverse populations. Together, they provide a more complete picture of how treatments perform outside clinical settings.
For readers managing chronic inflammatory skin concerns, this research emphasizes the importance of a long-term strategy. The coverage supports discussing goals beyond short-term change with a qualified dermatologist. It is helpful to track how a care plan addresses persistent itch and response durability. Understanding how to evaluate skin aging research helps you ask better questions during medical appointments.
Rather than relying on a single trial percentage to predict your personal outcome, ask how specific data applies to you. Discuss what follow-up is necessary if a particular treatment has helped you initially. It is crucial to monitor how your skin responds over months and years. Building a reliable skin longevity routine can complement clinical care, but it requires patience.
Any treatment change should be discussed directly with a medical professional. You should not infer medical advice strictly from congress coverage or a single study result. If you are experiencing persistent symptoms, your dermatologist is the most qualified resource for navigating these therapies. Those dealing with overlapping issues can learn about scalp conditions that affect hair to better understand systemic inflammation.
As dermatology transitions toward individualized cellular targets, the way we measure success is rapidly evolving. The focus on sustained quality of life marks a significant maturation in inflammatory skin care. With genetic and molecular insights becoming clearer, how long will it take before precision biopsy profiling becomes standard practice in clinics worldwide?
Stay connected for research and practical guidance on skin, hair, collagen, nutrition and beauty longevity. Clear ideas for people who want to understand how appearance changes with age and make better-informed choices over time.
Understand your skin, hair and body better without chasing every new trend, treatment or promise.
explore the Blog
